Reply to Auclin et al. Comment on “Hopkins et al. Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial. Cancers 2021, 13, 1176”

Detalles Bibliográficos
Autores principales: Hopkins, Ashley M., Kichenadasse, Ganessan, Abuhelwa, Ahmad Y., McKinnon, Ross A., Rowland, Andrew, Sorich, Michael J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Reply
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8345086/
https://www.ncbi.nlm.nih.gov/pubmed/34359664
http://dx.doi.org/10.3390/cancers13153763
_version_ 1783734545245274112
author Hopkins, Ashley M.
Kichenadasse, Ganessan
Abuhelwa, Ahmad Y.
McKinnon, Ross A.
Rowland, Andrew
Sorich, Michael J.
author_facet Hopkins, Ashley M.
Kichenadasse, Ganessan
Abuhelwa, Ahmad Y.
McKinnon, Ross A.
Rowland, Andrew
Sorich, Michael J.
author_sort Hopkins, Ashley M.
collection PubMed
description
format Online
Article
Text
id pubmed-8345086
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-83450862021-08-07 Reply to Auclin et al. Comment on “Hopkins et al. Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial. Cancers 2021, 13, 1176” Hopkins, Ashley M. Kichenadasse, Ganessan Abuhelwa, Ahmad Y. McKinnon, Ross A. Rowland, Andrew Sorich, Michael J. Cancers (Basel) Reply MDPI 2021-07-27 /pmc/articles/PMC8345086/ /pubmed/34359664 http://dx.doi.org/10.3390/cancers13153763 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Reply
Hopkins, Ashley M.
Kichenadasse, Ganessan
Abuhelwa, Ahmad Y.
McKinnon, Ross A.
Rowland, Andrew
Sorich, Michael J.
Reply to Auclin et al. Comment on “Hopkins et al. Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial. Cancers 2021, 13, 1176”
title Reply to Auclin et al. Comment on “Hopkins et al. Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial. Cancers 2021, 13, 1176”
title_full Reply to Auclin et al. Comment on “Hopkins et al. Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial. Cancers 2021, 13, 1176”
title_fullStr Reply to Auclin et al. Comment on “Hopkins et al. Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial. Cancers 2021, 13, 1176”
title_full_unstemmed Reply to Auclin et al. Comment on “Hopkins et al. Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial. Cancers 2021, 13, 1176”
title_short Reply to Auclin et al. Comment on “Hopkins et al. Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial. Cancers 2021, 13, 1176”
title_sort reply to auclin et al. comment on “hopkins et al. value of the lung immune prognostic index in patients with non-small cell lung cancer initiating first-line atezolizumab combination therapy: subgroup analysis of the impower150 trial. cancers 2021, 13, 1176”
topic Reply
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8345086/
https://www.ncbi.nlm.nih.gov/pubmed/34359664
http://dx.doi.org/10.3390/cancers13153763
work_keys_str_mv AT hopkinsashleym replytoauclinetalcommentonhopkinsetalvalueofthelungimmuneprognosticindexinpatientswithnonsmallcelllungcancerinitiatingfirstlineatezolizumabcombinationtherapysubgroupanalysisoftheimpower150trialcancers2021131176
AT kichenadasseganessan replytoauclinetalcommentonhopkinsetalvalueofthelungimmuneprognosticindexinpatientswithnonsmallcelllungcancerinitiatingfirstlineatezolizumabcombinationtherapysubgroupanalysisoftheimpower150trialcancers2021131176
AT abuhelwaahmady replytoauclinetalcommentonhopkinsetalvalueofthelungimmuneprognosticindexinpatientswithnonsmallcelllungcancerinitiatingfirstlineatezolizumabcombinationtherapysubgroupanalysisoftheimpower150trialcancers2021131176
AT mckinnonrossa replytoauclinetalcommentonhopkinsetalvalueofthelungimmuneprognosticindexinpatientswithnonsmallcelllungcancerinitiatingfirstlineatezolizumabcombinationtherapysubgroupanalysisoftheimpower150trialcancers2021131176
AT rowlandandrew replytoauclinetalcommentonhopkinsetalvalueofthelungimmuneprognosticindexinpatientswithnonsmallcelllungcancerinitiatingfirstlineatezolizumabcombinationtherapysubgroupanalysisoftheimpower150trialcancers2021131176
AT sorichmichaelj replytoauclinetalcommentonhopkinsetalvalueofthelungimmuneprognosticindexinpatientswithnonsmallcelllungcancerinitiatingfirstlineatezolizumabcombinationtherapysubgroupanalysisoftheimpower150trialcancers2021131176

Ejemplares similares